Abstract
Several viral and non-viral vectors have been developed for exogenous protein expression in specific cells. Conventionally, this purpose is achieved through the use of recombinant DNA. But mainly due to the risks associated with permanent genetic alteration of cells, safety and ethical concerns have been raised for the use of DNA-based vectors in human clinical therapy. In the last years, synthetic messenger RNA has emerged as powerful tool to deliver genetic information. RNA vectors exhibit several advantages compared to DNA and are particularly interesting for applications that require transient gene expression. RNA stability and translation efficiency can be increased by cis-acting structural elements in the RNA such as the 5’-cap, the poly(A)-tail, untranslated regions and the sequence of the coding region. Here we review recent developments in the optimization of messenger RNA as vector for modulation of protein expression emphasizing on stability, transfection and immunogenicity. In addition, we summarize current pre-clinical and clinical studies using RNA-based vectors for immunotherapy, T cell, stem cell as well as gene therapy.
Keywords: Gene therapy, genetic modifications, immunotherapy, in vitro transcription, mRNA, RNA stability, stem cells, T-cell therapy, transfection, translation
Current Gene Therapy
Title:mRNA as a Versatile Tool for Exogenous Protein Expression
Volume: 12 Issue: 5
Author(s): Andreas N. Kuhn, Tim Beißert, Petra Simon, Britta Vallazza, Janina Buck, Brian P. Davies, Ozlem Tureci and Ugur Sahin
Affiliation:
Keywords: Gene therapy, genetic modifications, immunotherapy, in vitro transcription, mRNA, RNA stability, stem cells, T-cell therapy, transfection, translation
Abstract: Several viral and non-viral vectors have been developed for exogenous protein expression in specific cells. Conventionally, this purpose is achieved through the use of recombinant DNA. But mainly due to the risks associated with permanent genetic alteration of cells, safety and ethical concerns have been raised for the use of DNA-based vectors in human clinical therapy. In the last years, synthetic messenger RNA has emerged as powerful tool to deliver genetic information. RNA vectors exhibit several advantages compared to DNA and are particularly interesting for applications that require transient gene expression. RNA stability and translation efficiency can be increased by cis-acting structural elements in the RNA such as the 5’-cap, the poly(A)-tail, untranslated regions and the sequence of the coding region. Here we review recent developments in the optimization of messenger RNA as vector for modulation of protein expression emphasizing on stability, transfection and immunogenicity. In addition, we summarize current pre-clinical and clinical studies using RNA-based vectors for immunotherapy, T cell, stem cell as well as gene therapy.
Export Options
About this article
Cite this article as:
N. Kuhn Andreas, Beißert Tim, Simon Petra, Vallazza Britta, Buck Janina, P. Davies Brian, Tureci Ozlem and Sahin Ugur, mRNA as a Versatile Tool for Exogenous Protein Expression, Current Gene Therapy 2012; 12 (5) . https://dx.doi.org/10.2174/156652312802762536
DOI https://dx.doi.org/10.2174/156652312802762536 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Methionine Aminopeptidases as Potential Targets for Treatment of Gastrointestinal Cancers and other Tumors
Current Drug Targets Recent Clinical Experience with Oncolytic Viruses
Current Pharmaceutical Biotechnology Bioconjugation of Ionophore Antibiotics: A Way to Obtain Hybrids with Potent Biological Activity
Mini-Reviews in Organic Chemistry The Role of Mesothelin in Tumor Progression and Targeted Therapy
Anti-Cancer Agents in Medicinal Chemistry Asbestos-Related Diseases: Still a Concern in Emerging Economies in the Absence of an International Ban
Current Respiratory Medicine Reviews Lung Cancer May Increase Serum Procalcitonin Level
Infectious Disorders - Drug Targets Epigenetics in Vascular Disease – Therapeutic Potential of New Agents
Current Vascular Pharmacology Dichotomous Life of DNA Binding High Mobility Group Box1 Protein in Human Health and Disease
Current Protein & Peptide Science Inhibiting Cyclin-Dependent Kinase / Cyclin Activity for the Treatment of Cancer and Cardiovascular Disease
Current Pharmaceutical Biotechnology PI3K Pathway Inhibitors: Better Not Left Alone
Current Pharmaceutical Design Exploring the Mitochondrial Apoptotic Cell Death Landscape and Associated Components Serving as Molecular Targets, Primarily for Synthetic and Natural Drugs Targeting Oncology Therapeutics
Current Molecular Pharmacology Therapeutic Potential of Targeting Glypican-3 in Hepatocellular Carcinoma
Anti-Cancer Agents in Medicinal Chemistry Status of Non-Classical Mononuclear Platinum Anticancer Drug Development
Mini-Reviews in Medicinal Chemistry Progress in Topical siRNA Delivery Approaches for Skin Disorders
Current Pharmaceutical Design Interplay between DNA Methyltransferase 1 and microRNAs During Tumorigenesis
Current Drug Targets Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry Farnesylated Proteins as Anticancer Drug Targets: From Laboratory to the Clinic
Current Medicinal Chemistry - Anti-Cancer Agents Protectors of the Mitochondrial Permeability Transition Pore Activated by Iron and Doxorubicin
Current Cancer Drug Targets Exploiting Innate γδ T Lymphocytes for Tumor Immunotherapy
Recent Patents on Biomarkers Boronic Acid-based Enzyme Inhibitors: A Review of Recent Progress
Current Medicinal Chemistry